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Abstract
Background: microRNA-122 (miR-122) is the most abundant and specific miRNA in the liver. It acts as an important
tumor suppressor in hepatocellular carcinoma (HCC) through regulating its target genes, but details of its own regulation
are largely unknown. Farnesoid X receptor (FXR), a transcription factor with multiple functions, plays an important role in
protecting against liver carcinogenesis, but it is unclear whether the anti-HCC effect of FXR is involved in the regulation
of miR-122.
Methods: The levels of miR-122 and FXR in HCC tissues and cell lines were examined by quantitative real-time
PCR (qRT-PCR). qRT-PCR was also used to detect the expression of miR-122 target genes at mRNA level, while Western
blotting was used to analyze that of their protein products. The effect of FXR on the transcriptional activity of miR-122
promoter was evaluated by a luciferase reporter assay. Electrophoretic mobility shift assay (EMSA) and chromatin
immunoprecipitation (ChIP) assay were performed to identify the FXR binding site within miR-122 promoter region.
The cell proliferation was analyzed by a CCK-8 assay. The influence of FXR on tumor growth and miR-122 expression in
vivo was monitored using HCC xenografts in nude mice.
Results: The expression of FXR was positively correlated with that of miR-122 in HCC tissues and cell lines. Activation of
FXR in HCC cells upregulated miR-122 expression and in turn downregulated the expression of miR-122 target
genes including insulin-like growth factor-1 receptor and cyclin G1. FXR bound directly to the DR2 element
(−338 to −325) in miR-122 promoter region, and enhanced the promoter’s transcriptional activity. Functional
experiments showed that the FXR-mediated upregulation of miR-122 suppressed the proliferation of HCC cells
in vitro and the growth of HCC xenografts in vivo.
Conclusions: miR-122 is a novel target gene of FXR, and the upregulation of miR-122 by FXR represses the
growth of HCC cells, suggesting that FXR may serve as a key transcriptional regulator for manipulating miR-122
expression, and the FXR/miR-122 pathway may therefore be a novel target for the treatment of HCC.
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Background
microRNAs (miRNAs), a family of small (~22-nucleotide)
endogenous noncoding RNAs [1], play important roles in
many cellular processes by targeting an estimated 10–30 %
of all protein-coding genes [2, 3]. miRNAs regulate target
genes through pairing interactions with specific mRNAs,
which can lead to degradation of target mRNAs or transla-
tion repression. Recently, growing evidence has shown that
a number of miRNAs are involved in the pathogenesis of
human cancers.
miR-122 is the most abundant miRNA (constituting
70 % of the total miRNA population) in the liver [4–6]. It
acts as an important tumor suppressor in hepatocellular
carcinoma (HCC) by targeting the genes involved in cell
proliferation, differentiation, apoptosis and angiogenesis
[7–10]. Previous reports have also shown that its expres-
sion is specifically reduced in primary HCC [11–13], so
the upregulation of miR-122 should be beneficial in the
prevention and treatment of HCC.
The farnesoid X receptor (FXR), a member of the nu-
clear receptor superfamily, is a transcription factor with
multiple functions that is mainly expressed in the liver, in-
testine, kidneys and adrenal glands [14]. Ligand-activated
FXR binds to the response elements of target genes either
as a classical FXR/retinoid X receptor alpha (RXRα) het-
erodimer or as a monomer [15–17], leading to changes in
their expression. FXR plays an important role in regulating
bile acid synthesis, and lipid and glucose metabolism [18].
Recently, it has also been shown to provide protection
against liver carcinogenesis through regulating tumor-
related genes such as gankyrin, nuclear factor (NF)-κB, N-
myc downstream regulated gene 2 (NDRG2), p53, and
carbohydrate response element binding protein [19–23].
However, it is unclear whether the anti-HCC effect of
FXR is involved in the regulation of miR-122.
In the present study, we demonstrated that the level of
FXR was positively correlated with that of miR-122 in
HCC tissues and cell lines. FXR upregulated the expression
of miR-122 by directly binding to the directed repeat sepa-
rated by two nucleotides (DR2 element) (−338 to −325) in
miR-122 promoter region, indicating that miR-122 is a
novel target gene of FXR. Functional experiments showed
that FXR-mediated upregulation of miR-122 suppressed
the proliferation of HCC cells in vitro and the growth of
HCC xenografts in vivo. These results suggest that FXR
may serve as a key transcriptional regulator for manipulat-
ing miR-122 expression, and that the FXR/miR-122 path-
way may be a novel target for the treatment of HCC.
Results
The level of FXR is positively correlated with that of
miR-122 in HCC tissues and cell lines
To investigate the relationship between FXR and miR-122,
their expression levels were examined using quantitative
real-time PCR (qRT-PCR) in 20 human HCC tissues
and the corresponding adjacent noncancerous tissues.
As shown in Fig. 1a and b, the expression of both FXR
and miR-122 in HCC tissues was lower than that in the
adjacent noncancerous tissues. Moreover, FXR expression
was positively correlated with that of miR-122 in HCC tis-
sues (R2 = 0.61, P < 0.01) (Fig. 1c). Similarly, the level of
FXR was also paralleled to that of miR-122 in HCC cell
lines (Fig. 1d) and there was a positive correlation between
them (R2 = 0.95, P < 0.01) (Fig. 1e). These results suggest
that FXR is involved in the regulation of miR-122.
FXR upregulates miR-122 expression and in turn downre-
gulates the expression of miR-122 target genes in HCC
cells
To investigate the regulation of miR-122 by FXR, Hep3B
cells were treated with the FXR agonist GW4064, then the
expression of miR-122 and its target genes including
insulin-like growth factor-1 receptor (IGF-1R) and cyclin
G1 were examined by qRT-PCR and Western blotting. As
shown in Fig. 2a–c, GW4064 dose-dependently upregu-
lated the expression of primary miR-122 (pri-miR-122) and
mature miR-122 (Fig. 2a), while downregulated the expres-
sion of IGF-1R and cyclin G1 (Fig. 2b and c). Moreover,
FXR activation also promoted miR-122 expression in other
HCC cell lines including Huh7, HepG2, PLC and SMMC-
7721 cells (Additional file 1: Figure S1). Knockdown of
FXR by small interfering RNA (siRNA) significantly attenu-
ated the GW4064-mediated upregulation of miR-122 and
downregulation of its target genes (Fig. 2d–f), indicating
that the effect of GW4064 on miR-122 expression is FXR-
specific. Furthermore, inhibition of miR-122 by its antago-
mir abolished the GW4064-mediated downregulation of
miR-122 target genes (Fig 2g and h), demonstrating that
FXR suppressed the expression of miR-122 target genes in
a miR-122-dependent manner (Namely, the FXR-induced
miR-122 is functional).
FXR enhances the transcriptional activity of miR-122
promoter
To clarify whether FXR upregulates miR-122 at tran-
scriptional level, luciferase reporter assays were per-
formed. The putative FXR response elements (FXREs) in
miR-122 promoter region were predicted using an online
algorithm (NUBIScan: http://www.nubiscan.unibas.ch/)
(Fig. 3a). Based on the findings in the prediction, a series
of luciferase reporters containing different fragments of
the promoter region were constructed and separately trans-
fected into HCC cells for luciferase assays. As shown in
Fig. 3b, the luciferase activity of construct pGL3-F4 (con-
taining the fragment −400 to +130) was much higher than
that of the other constructs when the cells were treated
with GW4064, suggesting that this region may harbor a
regulatory element. Mutation of FXRE/DR2 (−338 to −325)
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within the construct pGL3-F4 abolished the GW4064-
induced luciferase activity (Fig. 3c), indicating that the
FXRE/DR2 is important for FXR-enhanced transcriptional
activation of miR-122 promoter.
FXR binds directly to the FXRE/DR2 in miR-122 promoter
region
To determine the binding of FXR to the FXRE/DR2 in
miR-122 promoter region, we conducted an electrophor-
etic mobility shift assay (EMSA) and chromatin immuno-
precipitation (ChIP) assay. The sequences of DR2 and
mutant (Mut) DR2 probes were shown in Fig. 4a. EMSA
revealed that the interaction of labeled DR2 probe with
the nuclear extracts of HCC cells yielded a DNA/protein
shift band of expected mobility (Fig. 4b). This binding was
specific because it was competitively inhibited by the
addition of excess unlabeled (cold) DR2 probe but not
cold Mut DR2 probe, and because no obvious interaction
was observed between the Mut DR2 probe and HCC cell
nuclear extracts. Moreover, the addition of an anti-FXR
antibody to the reaction mixture resulted in a supershift
band (Fig. 4b), confirming that FXR is the protein interact-
ing with the DR2 probe in the nuclear extracts. As shown
in Fig. 4c, ChIP assay demonstrated that the anti-FXR
antibody precipitated the DNA fragment containing the
DR2 element, indicating that FXR binds directly to the
FXRE/DR2 in miR-122 promoter region in HCC cells.
Inhibition of miR-122 dramatically attenuates the FXR-
mediated growth suppression of HCC cells
To investigate whether the repressive effect of FXR on the
proliferation of HCC cells is mediated by the induction of
miR-122, antagomir-122 was used in CCK-8 assays. As
shown in Fig. 5, inhibition of miR-122 by its antagomir
markedly attenuated the GW4064-induced growth repres-
sion of HCC cells, strongly suggesting that the FXR-
mediated cell growth suppression is largely dependent on
miR-122 induction.
Fig. 1 The level of FXR is positively correlated with that of miR-122. a and b The expression of FXR mRNA (a) and mature miR-122 (b) in 20 human HCC
tissues and the corresponding adjacent noncancerous tissues was detected by qRT-PCR. c The correlation between the levels of FXR and
miR-122 in HCC tissues was analyzed using Pearson’s test (R2 = 0.61, P < 0.01). d The expression of FXR mRNA and mature miR-122 in HCC
cell lines (HepG2, Hep3B, Huh7, PLC, SMMC-7721, MHCC97L and MHCC97H) and hepatic cell line L02 was assayed by qRT-PCR. e The correlation
between the levels of FXR and miR-122 in HCC cell lines was analyzed using Pearson’s test (R2 = 0.95, P < 0.01). β-actin was used as a control for FXR
examination, while U6 snRNA as a control for miR-122 detection
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FXR-induced miR-122 is involved in the growth suppres-
sion of HCC xenografts in vivo
The above studies clearly demonstrated that the FXR-
induced upregulation of miR-122 plays an important
role in the FXR-mediated growth inhibition of HCC cells
in vitro. We next investigated the effects of FXR on
miR-122 induction and HCC growth in vivo. As shown
in Fig. 6a and b, treatment with GW4064 dramatically
repressed the growth of HCC xenografts in nude mice.
Immunohistochemical staining showed that GW4064
significantly reduced the expression of Ki67 (a marker of
proliferation) in the HCC xenografts (Fig. 6c). Consistent
with the in vitro findings, the activation of FXR by
GW4064 in vivo markedly increased miR-122 expression
and decreased that of miR-122 target genes including
IGF-1R and cyclin G1 in HCC xenografts (Fig. 6d and e).
These results suggest that FXR exerts its anti-HCC effects
through upregulating miR-122 expression in vivo.
Discussion
miR-122 is highly enriched in the liver, and plays an
important role in regulating hepatocyte development,
Fig. 2 FXR upregulates miR-122 expression and suppresses the expression of miR-122 target genes. a Hep3B cells were treated with GW4064
(0.5 or 5 μM) or vehicle DMSO for 24 h, and then the expression of pri-miR-122 and mature miR-122 was assayed using qRT-PCR. b and c Hep3B cells
were treated with GW4064 (0.5 or 5 μM) or vehicle DMSO for 48 h, and then the expression of miR-122 target genes including IGF-1R and cyclin G1 was
separately examined by qRT-PCR (b) and Western blotting (c). d Hep3B cells were transfected with 10 nM control siRNA or FXR siRNA for 24 h, and then
the level of FXR protein was detected by Western blotting. e and f After transfection with control siRNA or FXR siRNA for 24 h, Hep3B cells were treated
with vehicle DMSO or 5 μM GW4064 for 24 h, and then the expression of miR-122 and its target genes including IGF-1R and cyclin G1 was determined
by qRT-PCR (e) and Western blotting (f). g and h After transfection with 50 nM antagomir-122 or antagomir negative control (NC) for 6 h, Hep3B cells
were treated with vehicle DMSO or 5 μM GW4064 for 48 h, and then the expression of IGF-1R and cyclin G1 was analyzed by qRT-PCR (G) and Western
blotting (h). β-actin was used as a control for the examination of FXR, pri-miR-122, IGF-1R and cyclin G1, while U6 snRNA as a control for the detection
of mature miR-122. *P < 0.05, **P < 0.01 vs vehicle
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differentiation, lipid metabolism, and stress responses
[24–27]. Aberrant expression of miR-122 is closely related
with liver diseases. For examples, miR-122 represses hepa-
titis B virus (HBV) replication, and is decreased in the
livers of HBV-positive patients [28, 29]. Moreover, miR-122
is an important tumor suppressor of HCC [11, 13], and its
downregulation in human HCC tissues [8, 12] is associated
with metastasis and poor prognosis [30, 31]. Because of
many important roles of miR-122, it is necessary to
understand its regulatory mechanisms. Previous stud-
ies have shown that the transcriptional factors hepatocyte
nuclear factor 4 alpha (HNF4α) and CCAAT/enhancer
binding protein alpha (C/EBPα) can modulate miR-122 ex-
pression [30, 32].
The nuclear receptor FXR, a multiple functional tran-
scription factor, has been received increasing attention
Fig. 3 FXR enhances the transcriptional activity of miR-122 promoter. a Potential FXREs in miR-122 promoter region were predicted using
an online algorithm (NUBIScan: http://www.nubiscan.unibas.ch/). Transcription start sites (TSS, +1) are indicated by an arrow. b Huh7 cells
were co-transfected with renilla luciferase expression vector pRL-TK and one of a series of luciferase reporter constructs containing different fragments
of miR-122 promoter region. After 6 h incubation, the cells were treated with DMSO or 5 μM GW4064 for 24 h, and then dual luciferase assays were
performed. Firefly luciferase activity was normalized to that of renilla luciferase. Data are shown as means ± SD from three assays performed in triplicate.
c Huh7 cells were co-transfected with pRL-TK and either pGL3-F4(DR2)-WT (containing the wild-type DR2 element) or pGL3-F4(DR2)-Mut (containing
the mutant DR2 element) for 6 h. Subsequent treatment and luciferase assays were as performed in (b). *P < 0.05, **P < 0.01 vs vehicle
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as a therapeutic target for the treatment of liver carcin-
oma and other disorders such as metabolic diseases and
fibrosis. In this study, we show for the first time that
FXR upregulates miR-122 expression by binding directly
to the DR2 element in miR-122 promoter region, and,
moreover, that this upregulation plays an important role
in the FXR-mediated growth suppression of HCC cells
in vitro and in vivo.
Recently, Song et al. demonstrated that the nuclear re-
ceptor peroxisome proliferator-activated receptor gamma
(PPARγ) epigenetically regulates miR-122 expression in
HCC cells [33]. They found that treatment with the DNA
methylation inhibitor 5′-aza-2′deoxycytidine and histone
deacetylation inhibitor 4-phenylbutyric acid increased the
association of PPARγ/RXRα, but decreased that of its
corepressors (N-CoR and SMRT), with miR-122 regu-
latory elements, leading to an upregulation of miR-122
transcription. FXR and PPARγ share a number of charac-
teristics, including acting as a heterodimer with RXRα, al-
though FXR can also bind to the response elements as a
Fig. 4 FXR binds to the FXRE/DR2 in miR-122 promoter region. After treatment with the FXR agonist GW4064 (5 μM) for 48 h, Huh7 cells were harvested
for EMSA or ChIP assays. a The sequences of DR2 probe and mutant (Mut) DR2 probe are shown. The DR2 element is in bold, and the mutated bases are
underlined. b EMSA analysis of the binding of GW4064-treated Huh7 cell nuclear proteins to the FXRE/DR2. The reactions were analyzed
by electrophoresis in a nondenaturing 4 % polyacrylamide gel, followed by autoradiography. The cold DR2 or Mut DR2 probe was used at 100× excess
concentrations over the labeled probe in competition experiments. The antibody directed against FXR (anti-FXR) was used in supershift assays, taking
IgG as a negative control. c ChIP assays were performed using chromatin isolated from GW4064-treated Huh7 cells. Anti-FXR was used for
immunoprecipitation of the chromatin DNA fragment, taking IgG as a negative control. The precipitated DNA was extracted and amplified by PCR using
primers spanning the DR2 element. The input (total DNA extract) was used as positive PCR control. No antibody (no anti-FXR and IgG in the reaction) was
used as mock control
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Fig. 5 miR-122 inhibition dramatically attenuates the FXR-mediated growth suppression of HCC cells. a and b Huh7 (a) and Hep3B (b) cells were
transfected with antagomir NC or antagomir-122 for 24 h, and then treated with vehicle DMSO or 5 μM GW4064 for 48 h. Subsequently, the cell
proliferation was examined using the CCK-8 assay kit. Data are shown as the absorbance value at 450 nm. **P < 0.01 vs control
Fig. 6 FXR agonist represses the growth of HCC xenografts and upregulates miR-122 expression in vivo. a A total of 5 × 106 Hep3B cells were injected
into the right axillae of each nude mouse. After 11 days, the mice were randomly assigned to different groups (n = 5 per group), and treated daily with
vehicle or GW4064 at 40 mg/kg by intraperitoneal injection for 8 d. The xenograft tumor volume was monitored every other day. b HCC
xenografts were harvested for size comparison. c The expression of Ki67 (a marker of cell proliferation) in HCC xenografts was examined
by immunohistochemical staining. d and e The expression of miR-122, IGF-1R and cyclin G1 in HCC xenografts was separately detected
by qRT-PCR (d) and Western blotting (e). *P < 0.05, **P < 0.01 vs vehicle
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monomer, and recruits different cofactors from those of
PPARγ to regulate target genes. Therefore, it is not clear
whether FXR can epigenetically regulate miR-122 ex-
pression in the same way as PPARγ, which requires
further study.
Besides its regulation on miR-122, FXR uses other
mechanisms to protect against HCC including the repres-
sion of NF-κB activation in hepatocytes [20], indicating
that its anti-inflammatory properties may contribute to
HCC prevention. Moreover, FXR also inhibits the expres-
sion of gankyrin, a small proteasome subunit that medi-
ates the downregulation of tumor suppressor proteins
such as Rb, p53, HNF4α and C/EBPα in the development
of HCC [34]. Additionally, FXR directly promotes the
expression of HCC suppressors such as small hetero-
dimer partner and NDRG2, leading to the repression of
HCC development, growth and metastasis [35–37, 21].
These reports highlight the complexity of FXR anti-HCC
mechanisms, which should be investigated further.
Many target genes of miR-122 are involved in hepato-
carcinogenesis, HCC growth and metastasis, including
IGF-1R, cyclin G1, Wnt1, serum response factor, a disinte-
grin and metalloprotease 10 (ADAM10), ADAM17, cut-
like homeobox 1, pyruvate kinase muscle isozyme 2, and
pituitary tumor-transforming gene 1 binding factor
[24, 38, 39]. Of these, cyclin G1 and IGF-1R are in-
volved in cell proliferation. Cyclin G1 negatively regu-
lates p53 protein by recruiting B subunit of phosphatase
2A to dephosphorylate Mdm-2 [40]. Overexpression of
cyclin G1 enhances the growth of cancer cells, while its si-
lencing suppresses cell proliferation [41]. It can be directly
downregulated by miR-122, and the expression of cyclin
G1 and miR-122 is inversely correlated in HCC tissues
[42]. IGF-1R has recently been proposed as a novel target
for cancer treatment because it is overexpressed in a range
of cancers [43, 44]. miR-122 suppresses IGF-1R expression
and attenuates IGF-1R/Akt signaling, which sustains the
activity of glycogen synthase kinase 3 beta and in turn re-
presses cancer cell proliferation [30].
Conclusions
Our data show that the level of FXR is positively corre-
lated with that of miR-122 in HCC tissues and cell lines.
FXR upregulates the expression of miR-122 in HCC cells
by binding directly to the DR2 element (−338 to −325)
in miR-122 promoter region, which in turn downregu-
lates the expression of miR-122 target genes including
IGF-1R and cyclin G1. The FXR-mediated upregulation
of miR-122 suppresses the proliferation of HCC cells in
vitro and the growth of HCC xenografts in vivo in nude
mice. Although more studies are warranted to under-
stand the detailed molecular mechanisms by which miR-
122 regulates its target genes in HCC cells, our findings
demonstrate that miR-122 is a novel target gene of FXR.
These results also suggest that FXR could serve as a key
transcriptional regulator for manipulating miR-122 ex-
pression, and that the FXR/miR-122 pathway may be a
novel target for the treatment of HCC.
Materials and methods
Reagents
The FXR agonist GW4064 was purchased from Sigma
Chemical Company (St Louis, MO). Antagomir-122 (5′-C
AAACACCAUUGUCACACUCCA-3′), antagomir nega-
tive control (5′-CAGUACUUUUGUGUAGUACAA-3′),
siRNA for FXR (5′-CCUCAGGAAAUAACAAAUATT-3′),
and siRNA negative control (5′-UUCUCCGAACGUG
UCACGUTT-3′) were synthesized by GenePharma
(Shanghai, China). The all-in-one miRNA quantitative re-
verse transcriptase PCR detection kit was purchased from
GeneCopoeia (Guangzhou, China). The dual luciferase
assay system was from Promega (Madison, WI). The ChIP
kit was from Millipore (Billerica, MA). Antibodies against
FXR (sc-1204), IGF-1R (sc-712), cyclin G1 (sc-7865) and
β-actin (sc-47778) were purchased from Santa Cruz Bio-
technology (Dallas, TX).
Patient tissues and cell lines
A total of 20 HCC tissues and the corresponding adjacent
noncancerous tissues were obtained from Department of
Hepatobiliary Surgery, Xinqiao Hospital, Third Military
Medical University (Chongqing, China). Fresh tissue sam-
ples were collected and snap frozen in liquid nitrogen.
The study was approved by the ethics committee of Third
Military Medical University (Chongqing, China).
Human HCC cell lines HepG2 and Hep3B were from
American Type Culture Collection (Manassas, VA). The
other HCC cell lines including Huh7, PLC, SMMC-7721,
MHCC97L and MHCC97H, and hepatic cell line L02 were
purchased from China Center for Type Culture Collection
(Wuhan, China). All cells were cultured in Dulbecco’s
Modified Eagle’s medium supplemented with 10 % fetal
bovine serum, streptomycin (100 mg/mL) and penicillin
(100 U/mL) at 37 °C in a 5 % CO2 humid incubator.
Quantitative real-time PCR (qRT-PCR)
The expression of mature miR-122 was assayed using an
all-in-one miRNA quantitative reverse transcriptase PCR
detection kit according to the manufacturer’s protocol, nor-
malizing to U6 small nuclear RNA (snRNA). For examin-
ation of the mRNAs (including FXR, IGF-1R and cyclin G1
mRNAs) and pri-miR-122, total RNA was extracted with
TRIzol reagent (Invitrogen, Carlsbad, CA), and then the
first-strand cDNA was synthesized using M-MLV reverse
transcriptase (Invitrogen). Real-time PCR was performed
with SYBR green qPCR master mix (Promega). Relative
levels of the mRNAs and pri-miR-122 were normalized to
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that of β-actin mRNA. The primer sets for qRT-PCR are
listed in Additional file 1: Table S1.
Western blotting
Whole proteins were extracted from cells or tissues,
and protein concentrations were determined using the
Bradford protein assay kit (Beyotime, Shanghai, China).
The proteins (50 μg/lane) were separated by 10 % sodium
dodecyl sulfate (SDS) polyacrylamide gel electrophoresis
(PAGE) and transferred to polyvinylidene difluoride mem-
branes (Millipore). Subsequently, the membranes were
blocked with 5 % fat-free dry milk in Tris-buffered saline
containing 0.1 % Tween-20, and then incubated separately
with primary antibodies against FXR, IGF-1R, cyclin G1 or
β-actin at 4 °C overnight. After incubation with horseradish
peroxidase-conjugated secondary antibodies for 1 h, en-
hanced chemiluminescence detection reagents (Pierce,
Rockford, IL) were used to visualize the signals.
Plasmid construction and luciferase reporter assay
Putative FXREs in human miR-122 promoter region
were predicted using an online algorithm (NUBIScan:
http://www.nubiscan.unibas.ch/). Based on this pre-
diction (Fig. 3a), different lengths of human miR-122
promoter region were amplified by PCR using Huh7
cell genomic DNA as a template (The primer sequences
are listed in Additional file 1: Table S2). The fragments
were then separately inserted between KpnI and Hin-
dIII sites of the pGL3-basic vector (Promega), and the
resulting plasmids were named as follows with the frag-
ment of miR-122 promoter region specified: pGL3-F1
(−1100 to +130), pGL3-F2 (−1000 to +130), pGL3-F3
(−900 to +130), pGL3-F4 (−400 to +130) (also named
pGL3-F4(DR2)-WT), pGL3-F5 (−200 to +130), pGL3-F6
(−150 to +130), pGL3-F7 (−50 to +130) and pGL3-
F8 (+5 to +130). pGL3-F4(DR2)-Mut, derived from
pGL3-F4(DR2)-WT, contained mutations in the DR2
element (AATCGACCAGACTA, the mutated bases are
underlined).
For luciferase reporter assays, the above plasmids
were separately co-transfected with the renilla lucifer-
ase expression vector pRL-TK (Promega) into Huh7
cells using Lipofectamine 2000 (Invitrogen) according
to the manufacturer’s protocol. After 6 h incubation,
the cells were treated with vehicle dimethyl sulfoxide
(DMSO) or GW4064 (5 μM) for 24 h. The cells were
then harvested for the detection of luciferase activity
using the dual-luciferase assay kit (Promega) according to
the manufacturer’s instructions. Firefly luciferase activity
was normalized to that of renilla luciferase activity. All
transfection experiments were performed in triplicate and
repeated at least three times.
EMSA assay
Nuclear extracts were prepared from GW4064-treated
Huh7 cells using the NE-PER nuclear and cytoplasmic ex-
traction kit (Pierce), and the protein concentrations were
determined using Bradford protein assay kit (Beyotime).
The double-stranded probes were end-labeled with [γ-32P]-
ATP using T4 polynucleotide kinase (Takara, Shiga, Japan).
The binding reactions were performed separately in a 15 μl
reaction mixture containing 5× gel shift binding buffer
(5 mM MgCl2, 2.5 mM EDTA, 2.5 mM DTT, 250 mM
NaCl, 50 mM Tris–HCl (pH7.5), 25 mg/ml poly(dI-dC)
and 20 % glycerol (v/v)), and 5 μg nuclear proteins. For
competition experiments, unlabeled (cold) DR2 or Mut
DR2 probe was added to the reaction mixture at 100× ex-
cess concentrations over the labeled probe. The mixtures
were then incubated at room temperature for 10 min. For
supershift assays, 4 μg antibody against FXR or control IgG
was added to the reaction mixture and incubated on ice for
30 min. Subsequently, 6000 cpm of 32P-labeled probe was
added to each reaction mixture and incubated at room
temperature for 20 min. All the reaction products were an-
alyzed by electrophoresis in a 4 % nondenaturing polyacryl-
amide gel (59 : 1, acrylamide : bisacrylamide) in 0.5× Tris-
borate-EDTA. The gel was then dried and exposed to x-ray
film overnight at −70 °C for autoradiography.
ChIP assay
ChIP assays were performed using the ChIP Assay kit ac-
cording to the manufacturer’s instructions. Briefly, Huh7
cells were treated with 5 μM GW4064 for 48 h, and then
incubated with formaldehyde at a final concentration of
1 % (v/v) for 10 min at 37 °C to cross-link the nuclear pro-
teins to DNA. Subsequently, the cells were harvested by
centrifugation at 4 °C for 4 min at 1000 × g, and then lysed
in 200 μl SDS lysis buffer (1 % SDS, 10 mM EDTA
and 50 mM Tris–HCl (pH 8.1)). Chromation sonication
was performed to shear the DNA to an average length of
200–1000 bp, followed by the immunoprecipitation with
the antibody against FXR, taking IgG as a control. The
precipitated DNA was extracted and subjected to PCR
amplification using the primer pair spanning the FXRE/
DR2 in miR-122 promoter region (−390 to −261) (forward
primer: 5′-AACTTAGTAGGCTCCTGTGACCGG − 3′,
and reverse primer: 5′ −ATCTTCCCCTCAGAAC CCCA
ACT − 3′).
Cell proliferation assay
The cell proliferation was examined using the CCK-8
assay kit (Beyotime) according to the manufacturer’s in-
structions. Briefly, Huh7 or Hep3B cells were seeded onto
96-well plates (2 × 103 cells/well) and transfected with
antagomir-122 or the control antagomir (NC) for 24 h.
The cells were then treated with vehicle DMSO or 5 μM
GW4064 for 48 h, followed by the addition of 10 μL
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WST-8 dye to each well. After incubation at 37 °C for 4 h,
the absorbance value at 450 nm was determined using a
microplate reader.
In vivo experiments
Eight-week-old male nude mice were purchased from the
Laboratory Animal Center of China (Shanghai, China) and
cared for under the guidelines of the Animal Care Com-
mittee of Third Military Medical University (Chongqing,
China). A total of 5 × 106 Hep3B cells in 150 μl phosphate-
buffered saline were subcutaneously injected into the right
axilla of each nude mouse. After 11 days, the mice were
randomly assigned to control and test groups (n = 5 per
group). They then received a daily intraperitoneal injection
of 40 mg/kg GW4064 (test group) or vehicle (control
group) for 8 d. The length and width of the xenograft tu-
mors were monitored every other day, and their volumes
were estimated using the following formula: volume =
width2 × length × 1/2. Subsequently, the mice were sacri-
ficed, and the tumors were harvested for analysis of the
expression of Ki67, miR-122 and its target genes including
IGF-1R and cyclin G1.
Immunohistochemical staining
The harvested xenograft tumors were fixed with 4 % poly-
oxymethylene, and then paraffin-embedded and sectioned.
The sections were incubated with the primary antibody
against Ki67 (ZSGB-BIO, Beijing, China), followed by
a peroxidase-conjugated secondary antibody. 3,3′-di-
aminobenzidine was used to visualize the Ki67 signal,
and the sections were observed under Olympus IX81
photomicroscope.
Statistical analysis
All data were expressed as means ± SD unless otherwise
stated. Statistical analysis was performed using SPSS13.0
software. Differences between two groups were deter-
mined by the Student’s t-test, and correlation analysis
was performed using Pearson’s test. P < 0.05 was defined
as statistically significant.
Additional file
Additional file 1: Figure S1. Activation of FXR upregulates miR-122
expression in HCC cells. HepG2, Huh7, PLC and SMMC-7721 cells were
separately treated with GW4064 (5 μM) or vehicle DMSO for 24 h, and then
the expression of pri-miR-122 (A) and mature miR-122 (B) was examined by
qRT-PCR. **P < 0.01 vs vehicle. Table S1. The primer sets for qRT-PCR. Table S2.
The primer sets for PCR amplification of different fragments of human
miR-122 promoter region. (DOC 82 kb)
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